ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2071 entries already.
Digital pathology specialist AIgnostics GmbH has topped up its cash position to US$55m with a US$34m Series B financing. The money will be used to optimise the company’s RudolfV Foundation Model and to develop and offer new services for target and biomarker identification selection, particularly in the US pharma market.
Italian obesity gene therapy developer Resalis Therapeutics srl has gained an equity investment from French pharma major Sanofi SA sufficient to finance its miRNA-22 antisense blocker RES-010 through Phase II proof-of-concept.
Belgian UCB SA and British Cancer UK have started a second clinical study within their multi-year partnership to evaluate the safety and tolerable dose of UCB4594 in patients with advanced cancers.
Swiss Ikerian AG’s US-subsidiary, RetinAI U.S. Inc. has announced the first close of an CHF6.73m Series B financing with new and existing investors to advance its AI-based image analysis platform alongside a strategic partnership.
German antibody specialist YUMAB GmbH has inked a collaboration agreement with Japanese MOLCURE Inc aimed at using the company’s zero-shot AI technology for antibody discovery.
Dutch Forbion has announced its largest fundraising to date, with Forbion’s Growth Opportunities Fund III raising €1.2bn and Forbion Ventures Fund VII raising €890m.
Lundbeck A/S is set to take over all shares of neurology specialist Longboard Pharmaceuticals Inc worth US$2.6bn to strengthen its pipeline with the Phase III 5-hydroxythyprytamaine 2C receptor super-agonist bexicaserine to treat 11 rare neurological conditions.
German diagnostics company Sphingotec GmbH has licensed its real-time kidney function test to US diagnostics giant Beckman Coulter allowing it to expand its business to the US as announced earlier this month.
AviadoBio Ltd has cashed in €30m upfront and €20m as an equity investment from Astellas Pharma Inc for signing a licence option agreement for its Phase I/II gene therapy programme AVR-01.
Kurma Partners announced a first closing of its new Biofund IV at €140m targeted to raise €250m to finance 16-20 life science companies.